A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)

Phase 4CompletedNCT00140972

Organon and Co160 enrolled

Overview

A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

160

Conditions

Osteoarthritis

Interventions

MK0663; etoricoxib / Duration of Treatment:4 WeeksDRUG

Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 WeeksDRUG

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chinese males or females at least 40 years of age with osteoarthritis of the knee or hip

Outcomes

Primary Outcomes

WOMAC pain subscale

Secondary Outcomes

WOMAC Physical function subscale; WOMAC Stiffness subscale; Patient Global Assessment of Response to Therapy; Investigator Global Assessment of Disease Status

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.